Latest Equity Incentives News

Mesoblast has commercially launched Ryoncil in the US for pediatric acute GVHD, backed by a strong cash position and advancing multiple cell therapy programs.

Anteris Technologies Global Corp. has filed an amended 10-K to disclose comprehensive governance, executive pay, and related party transactions for fiscal 2024, completing its annual SEC reporting obligations.

Macarthur Minerals Limited reported a substantial loss of A$25.6 million for the nine months ending December 31, 2024, driven largely by the sale of its Hematite Project. Despite this setback, the company outlines plans for future funding and operational adjustments to sustain its business.

FireFly Metals Ltd reported a reduced half-year loss of A$5.7 million for December 2024, bolstered by a significant increase in cash reserves and strategic asset acquisitions in Canada and Australia.

Bastion Minerals has appointed Allister Caird as CEO and Dr Julian Stephens as Chief of Exploration and Strategy, signaling a strategic push to advance its Canadian copper projects with seasoned leadership.

Summit Minerals appoints Dr. Matthew Cobb as CEO to accelerate development of its Equador Niobium and Rare Earth Elements Project in Brazil, while reshuffling leadership to bolster operational focus.

Mesoblast has secured FDA approval for Ryoncil®, the first mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in children, while raising A$260 million to accelerate clinical trials and commercial rollout.

Activeport Group Ltd reported steady revenue of $2.5 million in Q2 FY25, maintaining a stable cost structure post-restructure and positioning itself for growth through new projects and a significant GPU orchestration licensing deal.